Plasma cholesteryl ester transfer protein is predominantly derived from Kupffer cells

The role of Kupffer cells (KCs) in the pathophysiology of the liver has been firmly established. Nevertheless, KCs have been underexplored as a target for diagnosis and treatment of liver diseases owing to the lack of noninvasive diagnostic tests. We addressed the hypothesis that cholesteryl ester transfer protein (CETP) is mainly derived from KCs and may predict KC content. Microarray analysis of liver and adipose tissue biopsies, obtained from 93 obese subjects who underwent elective bariatric surgery, showed that expression of CETP is markedly higher in liver than adipose tissue. Hepatic expression of CETP correlated strongly with that of KC markers, and CETP messenger RNA and protein colocalized specifically with KCs in human liver sections. Hepatic KC content as well as hepatic CETP expression correlated strongly with plasma CETP concentration. Mechanistic and intervention studies on the role of KCs in determining the plasma CETP concentration were performed in a transgenic (Tg) mouse model expressing human CETP. Selective elimination of KCs from the liver in CETP Tg mice virtually abolished hepatic CETP expression and largely reduced plasma CETP concentration, consequently improving the lipoprotein profile. Conversely, augmentation of KCs after Bacille‐Calemette‐Guérin vaccination largely increased hepatic CETP expression and plasma CETP. Also, lipid‐lowering drugs fenofibrate and niacin reduced liver KC content, accompanied by reduced plasma CETP concentration. Conclusions: Plasma CETP is predominantly derived from KCs, and plasma CETP level predicts hepatic KC content in humans.(Hepatology 2015;62:1710–1722)

[1]  Jingyuan Fu,et al.  Determining the association between adipokine expression in multiple tissues and phenotypic features of non-alcoholic fatty liver disease in obesity , 2015, Nutrition & Diabetes.

[2]  A. Masclee,et al.  Trapping of oxidized LDL in lysosomes of Kupffer cells is a trigger for hepatic inflammation , 2013, Liver international : official journal of the International Association for the Study of the Liver.

[3]  J. Jukema,et al.  Journey Through Cholesteryl Ester Transfer Protein Inhibition: From Bench to Bedside , 2013, Circulation. Cardiovascular quality and outcomes.

[4]  Virginia Nguyen,et al.  Kuppfer Cells Trigger Nonalcoholic Steatohepatitis Development in Diet-induced Mouse Model through Tumor Necrosis Factor-α Production* , 2012, The Journal of Biological Chemistry.

[5]  A. Boonstra,et al.  Kupffer cells express a unique combination of phenotypic and functional characteristics compared with splenic and peritoneal macrophages , 2012, Journal of leukocyte biology.

[6]  R. Xavier,et al.  Bacille Calmette-Guérin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes , 2012, Proceedings of the National Academy of Sciences.

[7]  T. V. van Berkel,et al.  Niacin reduces plasma CETP levels by diminishing liver macrophage content in CETP transgenic mice. , 2012, Biochemical pharmacology.

[8]  D. Torres,et al.  Features, diagnosis, and treatment of nonalcoholic fatty liver disease. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  Leif Groop,et al.  Differential gene expression in adipose tissue from obese human subjects during weight loss and weight maintenance. , 2012, The American journal of clinical nutrition.

[10]  L. N. Valenti,et al.  Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. , 2012, International journal of molecular medicine.

[11]  N. Van Rooijen,et al.  Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. , 2012, American journal of physiology. Gastrointestinal and liver physiology.

[12]  G. Musso,et al.  Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials , 2012, Diabetologia.

[13]  H. Pijl,et al.  Prolonged Caloric Restriction in Obese Patients With Type 2 Diabetes Mellitus Decreases Plasma CETP and Increases Apolipoprotein AI Levels Without Improving the Cholesterol Efflux Properties of HDL , 2011, Diabetes Care.

[14]  Bin Zhang,et al.  A survey of the genetics of stomach, liver, and adipose gene expression from a morbidly obese cohort. , 2011, Genome research.

[15]  C. Wijmenga,et al.  Co-expressed immune and metabolic genes in visceral and subcutaneous adipose tissue from severely obese individuals are associated with plasma HDL and glucose levels: a microarray study , 2010, BMC Medical Genomics.

[16]  B. Wolfe,et al.  Effects of weight loss, induced by gastric bypass surgery, on HDL remodeling in obese women , 2010, Journal of Lipid Research.

[17]  S. Caldwell,et al.  Epidemiology and natural history of non-alcoholic steatohepatitis. , 2009, Clinics in liver disease.

[18]  E. Solary,et al.  Liver X Receptor–Mediated Induction of Cholesteryl Ester Transfer Protein Expression Is Selectively Impaired in Inflammatory Macrophages , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[19]  N. Fournier,et al.  Torcetrapib Differentially Modulates the Biological Activities of HDL2 and HDL3 Particles in the Reverse Cholesterol Transport Pathway , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Jukema,et al.  Niacin Increases HDL by Reducing Hepatic Expression and Plasma Levels of Cholesteryl Ester Transfer Protein in APOE*3Leiden.CETP Mice , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[21]  S. Offermanns,et al.  Nicotinic acid: an old drug with a promising future , 2008, British journal of pharmacology.

[22]  M. Caulfield,et al.  Effects of torcetrapib in patients at high risk for coronary events. , 2007, The New England journal of medicine.

[23]  M. Yeh,et al.  Pathology of nonalcoholic fatty liver disease. , 2007, American journal of clinical pathology.

[24]  J. Jukema,et al.  Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression Published, JLR Papers in Press, May 24, 2007. , 2007, Journal of Lipid Research.

[25]  Joong-Won Park,et al.  Predictors reflecting the pathological severity of non‐alcoholic fatty liver disease: Comprehensive study of clinical and immunohistochemical findings in younger Asian patients , 2007, Journal of gastroenterology and hepatology.

[26]  M. Jauhiainen,et al.  Important Role for Bone Marrow–Derived Cholesteryl Ester Transfer Protein in Lipoprotein Cholesterol Redistribution and Atherosclerotic Lesion Development in LDL Receptor Knockout Mice , 2007, Circulation research.

[27]  A. Gerbes,et al.  Role of Kupffer cells in host defense and liver disease , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[28]  J. Jukema,et al.  Cholesteryl Ester Transfer Protein Decreases High-Density Lipoprotein and Severely Aggravates Atherosclerosis in APOE*3-Leiden Mice , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[29]  H. Denk,et al.  Cytokine‐independent repression of rodent Ntcp in obstructive cholestasis , 2005, Hepatology.

[30]  J. Kastelein,et al.  Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. , 2005, Journal of the American College of Cardiology.

[31]  A. Zwinderman,et al.  The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia. , 2004, Atherosclerosis.

[32]  A. Tall,et al.  Sterol upregulation of human CETP expression in vitro and in transgenic mice by an LXR element. , 2000, The Journal of clinical investigation.

[33]  K. Hatakeyama,et al.  The role of Kupffer cells in liver regeneration. , 1999, Archives of histology and cytology.

[34]  R. McPherson,et al.  Relationship of adipose tissue cholesteryl ester transfer protein (CETP) mRNA to plasma concentrations of CETP in man. , 1998, Atherosclerosis.

[35]  A. Tall,et al.  Decreased cholesteryl ester transfer protein (CETP) mRNA and protein and increased high density lipoprotein following lipopolysaccharide administration in human CETP transgenic mice. , 1995, The Journal of clinical investigation.

[36]  A. Tall.  Plasma cholesteryl ester transfer protein. , 1993, Journal of lipid research.

[37]  A. Tall,et al.  Dietary cholesterol increases transcription of the human cholesteryl ester transfer protein gene in transgenic mice. Dependence on natural flanking sequences. , 1992, The Journal of clinical investigation.

[38]  M. Pape,et al.  Molecular cloning, sequence, and expression of cynomolgus monkey cholesteryl ester transfer protein. Inverse correlation between hepatic cholesteryl ester transfer protein mRNA levels and plasma high density lipoprotein levels. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[39]  R. McCuskey,et al.  Kupffer cell function in host defense. , 1987, Reviews of infectious diseases.

[40]  C. Fielding,et al.  Cloning and sequencing of human cholesteryl ester transfer protein cDNA , 1987, Nature.

[41]  Takashi Yamamoto,et al.  SERIES : Hepatic sinusoidal cells in liver physiology and pathology , 2004 .

[42]  M. Guerin,et al.  Pharmacological modulation of cholesteryl ester transfer protein, a new therapeutic target in atherogenic dyslipidemia. , 2004, Pharmacology & therapeutics.